Other DLL3-targeting bispecific T-cell engagers, such as BI-764532 and HPN328, that enhanced the activity of CD4+ and CD8+ T cells against DLL3-expressing SCLC in mice (104, 105), are being studied. Here, CD8A is linked to small cell lung carcinoma.